SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals informs about press release

10 Jul 2025 Evaluate
SMS Pharmaceuticals has informed that it enclosed copies of the newspaper advertisement published on 10th July, 2025, informing the shareholders about transfer of shares to Investor Education Protection Fund (IEPF) pertaining to the unpaid/ unclaimed dividend for the financial year 2017 -2018. The advertisement has been published in the following newspapers: Financial Express (in English language); Nava Telangana (in Telugu language). The newspaper advertisements is also made available on the website of the Company www.smspharma.com at Investors Section.

The above information is a part of company’s filings submitted to BSE.

SMS Pharmaceuticals Share Price

357.40 3.60 (1.02%)
05-Jun-2026 09:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.40
Dr. Reddys Lab 1277.45
Cipla 1391.40
Zydus Lifesciences 1087.25
Lupin 2291.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×